Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia

OBJECTIVE: Since 2016, bevacizumab has been widely used to treat metastatic colorectal cancer (mCRC) in Indonesia. Nevertheless, the high cost of bevacizumab has raised the question of whether the therapy is considered cost-effective and should be included in the national health insurance system. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristin, Erna, Endarti, Dwi, Khoe, Levina Chandra, Taroeno-Hariadi, Kartika Widayati, Trijayanti, Christina, Armansyah, Armansyah, Sastroasmoro, Sudigdo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418847/
https://www.ncbi.nlm.nih.gov/pubmed/34181352
http://dx.doi.org/10.31557/APJCP.2021.22.6.1921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418847/
https://www.ncbi.nlm.nih.gov/pubmed/34181352
http://dx.doi.org/10.31557/APJCP.2021.22.6.1921

Ejemplares similares